Vineti Inc., a software provider for personalized therapeutics, has opened a new regional headquarters in Bethesda, MD, to support the expanding cell and gene therapy corridor on the East Coast.
 
“Vineti is growing rapidly alongside the thriving ecosystem of personalized therapeutics,” said Amy DuRoss, chief executive officer, Vineti. “While we’ve always enjoyed supporting our East Coast clients, we’re now very excited to establish ourselves directly in the community, and further solidify our business leadership and connections in the personalized therapeutic ecosystem.”
 
More than 1,000 cell and gene therapy clinical trials are currently active globally, with a large concentration of personalized therapy development and manufacturing located in states such as Maryland, Massachusetts, New Jersey and Pennsylvania. Vineti’s Personalized Therapy Management platform is already enabling several therapeutic pipelines in the region. Vineti’s platform is the first commercially available, cloud-based software platform to safely and efficiently move patient-based personalized therapies through clinical development and into mainstream medicine at scale.
 
“We’re excited to see the continued growth of the advanced therapy sector in this region,” said Morrie Ruffin, managing partner of Adjuvant Partners, and co-founder and senior advisor to the Washington D.C.-based Alliance for Regenerative Medicine.
 
Ruffin noted that a range of industry leaders, including Kite Pharma, Lonza, Autolus Therapeutics, Paragon Bioservices, Lentigen/Miltenyi, and Orgenesis/Masthercell have established facilities in the Washington D.C region. 
 
“Alongside other recent announcements of new cell and gene therapy investment in the metro D.C area, this ongoing growth demonstrates our sector’s overall forward momentum,” Ruffin said.